Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN): This Pharma Company Needs to Take Urgent Measures

AstraZeneca plc (ADR) (NYSE:AZN) has cash and equivalents of approximately $9 billion, which is much less when compared to Pfizer. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is also in trouble due to its Copaxone expiry, and has adopted a pretty unique approach to facing this crisis. The company is trying to find new applications for its existing compounds and focusing on expanding its OTC segment.

Bottom line

AstraZeneca is headed in the right direction, but the company will have to take more urgent measures to address its revenue decline. This will not be as easy as acquiring a small high potential bio-pharmaceutical company, because some major players are already on the hunt for promising acquisition targets.

The article This Pharma Company Needs to Take Urgent Measures originally appeared on Fool.com and is written by Mohsin Saeed.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.